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LETTERS TO THE EDITOR
Topical Retinoids:
Another Piece for the
Retinoid-Cigarette-
Lung Cancer Puzzle?
To the Editor:
The possibility of a role for topical
retinoids might add an additional piece
to the retinoid-cigarette-lung cancer
puzzle.1
A poster2 at the 2005 annual meet-
ing of The Society for Investigative Der-
matology described the halting of a top-
ical retinoid study because of an excess
of deaths from lung cancer and pulmo-
nary disease in the treated group. A
10-center, 1131-participant trial had
been sponsored by the Department of
Veterans Affairs to study the ability of
0.1% tretinoin cream to reduce the de-
velopment of keratinocyte carcinoma.
Participants (average age, 71 years) ap-
plied tretinoin cream or placebo to their
face and ears every day for 6 years. The
study was stopped 6 months before
completion because of deaths from pul-
monary disease (12 versus two) and
non-small cell lung cancer (11 versus 4)
but not other cancers (20 versus 18) or
cardiac disease (19 versus 16) in the
tretinoin cream versus placebo groups.
Presenters of the poster suggested
that failure to randomize for factors such
as smoking had flawed the study design.
With further analysis, they found differ-
ences in Charlson comorbidity index,
age, and smoking. Each of those differ-
ences favored worse prognosis in the
tretinoin group, but all differences were
small and statistically insignificant. Cox
multivariate regression with those vari-
ables and treatment group revealed that,
with joint consideration of all of those
variables, the mortality difference be-
tween the groups was not statistically
significant.
The authors concluded that treti-
noin did not cause the mortality differ-
ence between the groups and that, in
retrospect, the termination of the inter-
vention was unnecessary. They did not
consider the possibility that absorbed
tretinoin might have acted like dietary
carotinoid in cigarette smokers.
A possible mechanism for such an
effect was described in 2004 by Harder
et al.3 from Kiel and Stockholm. They
added tretinoin to foreskin keratinocytes
in cell culture and looked for an effect
on the synthesis of beta-defensins. There
was a profound reduction in defensins-1,
-2, -3, and -4. Their conclusion was that
retinoic acid “might downregulate the
innate chemical defense system of hu-
man skin.”
Like the skin, the bronchial epi-
thelium confronts the environment and,
like the skin, uses defensins as part of its
innate immune response capability.4
Bronchial defensins are increased in squa-
mous metaplasia and in lung cancer.
By reducing the defensin effect,
absorbed topical retinoid could be re-
sponsible for an increase in the appear-
ance of lung cancer without the need to
postulate a carcinogenic mechanism. The
same explanation would account for the
excess of deaths from non-malignant pul-
monary disease in the halted VA trial.
Whether enough tretinoin is ab-
sorbed from topical application to affect
the bronchial production of defensins or
other agents of innate immunity needs to
be investigated. The Renova (OrthoNeu-
trogena, Raritan, NJ) package insert de-
scribes the systemic absorption of treti-
noin as ranging from 1% to 31%
depending on the condition of the af-
fected skin, although a study from The
Johnson and Johnson Skin Research
Center reported that plasma levels of
tretinoin were not significantly different
from pretreatment levels even after
chronic use.5
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Temozolomide as
Prophylaxis for Brain
Metastasis in Non-small
Cell Lung Cancer
To the Editor:
We read with interest the article
by Choong et al.1 regarding the use of
temozolomide and irinotecan in non-
small cell lung cancer (NSCLC) with
particular attention to the development
of brain metastasis. They suggested that
temozolomide had “little role in the pro-
phylaxis against metastasis in NSCLC”
based on their results. They observed
only three of 37 patients developing
brain metastasis in this phase II study.
(Nine patients entered the study with a
history of radiation-treated brain metas-
tasis; the patients had no clinical evi-
dence of central nervous system (CNS)
progression while on study.) As 50% of
patients with NSCLC would be ex-
pected to develop brain metastasis (with
median time to development of 6–9
months), we came to a different conclu-
sion. In this regard, in a prospective trial
of well-staged (including head magnetic
resonance imaging) stage IIIA and IIIB
NSCLC that we reported,2 20 of 25
patients treated with combined modality
therapy relapsed within less than 12
months, and of these, eight patients
(40% of all relapsing patients, 32% ofBoth authors hold rights to an applied-for patent for
a non-retinoid anti-wrinkle product distributed
by Flinn Laboratories, Inc., Memphis, TN.
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all patients) failed initially in the CNS.
Four additional patients subsequently
developed CNS metastases, for an over-
all CNS failure rate of 12 of 20 (relaps-
ing) patients, or 60%, representing al-
most 50% of all well-staged stage IIIA
and B NSCLC patients failing in the
CNS. (These failures were detected clin-
ically because routine post-study mag-
netic resonance imaging was not per-
formed). Thus, we hypothesize that the
low incidence of 8% CNS metastasis in
the Choong et al. study might in fact
suggest that temozolomide could poten-
tially have controlled microscopic CNS
disease in a proportion of patients.
Consistent with this supposition,
an earlier study reported by Adonizio et
al.3 using temozolomide as a single
agent produced similar results: five of
38 patients entered the study with
treated brain metastasis; two had CNS
progression and only one patient devel-
oped brain metastasis on study for an
incidence of 3%.
These results, taken collectively,
provide putative support for a well-
structured prospective clinical trial to
test the value of temozolomide for “pro-
phylaxis” (i.e., in reality, the treatment
of micrometastatic disease) of the CNS
in NSCLC. Such a study is now in its
final stages of development as a joint
project between the University of Wis-
consin Comprehensive Cancer Center,
the University of Texas Southwestern
Cancer Center, Dallas (Dr. Joan
Schiller), and the Fox Chase Cancer
Center, Philadelphia (Dr. Cory Langer).
H. Ian Robins, MD, PhD
Anne M. Traynor, MD
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Reply to the Letter by
Robins et al.
To the Editor:
On behalf of the coauthors, we are
replying to the letter by Dr. Robins and
colleagues.
In our study evaluating temozolo-
mide and irinotecan as second-line
agents, we determined that the response
rate was only 9% with a short median
time to progression of 1.8 months. As a
result, the duration of treatment was
short (median two cycles or 6 weeks). In
this brief period, 67% of our subjects
had progressive disease including three
patients who developed new symptom-
atic brain metastasis. Because brain im-
aging was not required post-study, the
incidence of asymptomatic brain metas-
tasis is unknown but probably higher
than 8%.1 In addition, our trial was not
designed to specifically address the ef-
fect of temozolomide on brain metasta-
sis. We agree that the role of temozolo-
mide as prophylaxis against central
nervous system metastasis should be
evaluated in a large, well-designed pro-
spective trial.
Thank you very much for allow-
ing us to reply.
Nicholas W. Choong MD, and
Everett E. Vokes, MD
Section of Hematology-Oncology
University of Chicago Medical Center,
Chicago, Illinois
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Efficacy of Gefitinib in a
Patient with Lung
Cancer Associated with
Idiopathic Pulmonary
Fibrosis
To the Editor:
Lung cancer frequently develops
in patients with idiopathic pulmonary
fibrosis (IPF).1 However, there is no
established or standardized chemother-
apy to date for advanced lung cancer
associated with IPF. Gefitinib, an oral
inhibitor of epidermal growth factor re-
ceptor (EGFR) tyrosine kinase domain,
is effective for selected patients with
advanced non-small cell lung cancer
(NSCLC).2 However, the incidence of
interstitial lung disease (ILD) caused by
gefitinib is as high as 5% in Japan, and
preexisting pulmonary fibrosis is con-
sidered to be a risk factor for developing
ILD.3,4 We report the case of a patient
with stage IV adenocarcinoma associ-
ated with IPF who was successfully
treated with gefitinib.
A 77-year-old man was admitted
to our hospital for the evaluation of a
mass lesion on chest radiograph. He
had smoked one pack of cigarettes
daily for 59 years. On examination,
fine crackles were heard at both lung
bases. A chest computed tomography
(CT) scan revealed a lobulated mass,
66  50 mm in diameter, in the right
upper lobe with enlargement of para-
tracheal, pretracheal, and subcarinal
lymph nodes (Figure 1A). In addition,
honeycombing was observed in the
lung base bilaterally (Figure 1B). A
diagnosis of adenocarcinoma was
made by transbronchial biopsy. Brain
CT disclosed a metastatic lesion, 5
mm in diameter, in the right parietal
lobe. The patient was diagnosed as
having stage IV (cT2N2M1) NSCLC
associated with IPF. At first, the brain
metastasis was treated by stereotactic
radiosurgery (gamma knife). Subse-
quently, the patient preferred gefitinib
for the first-line therapy to intravenous
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